Drug Safety in Geriatric Patients: Current Status and Proposed Way Forward

Giovanni Furlan (), Pia Caduff-Janosa, Laura Sottosanti, Emiliano Cappello, Giulia Valdiserra and Marco Tuccori
Additional contact information
Giovanni Furlan: Pfizer s.r.l., Safety Surveillance and Risk Management
Pia Caduff-Janosa: Uppsala Monitoring Centre
Laura Sottosanti: Agenzia Italiana del Farmaco
Emiliano Cappello: University Hospital of Pisa
Giulia Valdiserra: University Hospital of Pisa
Marco Tuccori: University Hospital of Pisa

Drug Safety, 2020, vol. 43, issue 9, No 3, 853-866

Abstract: Abstract Elderly patients are the main users of drugs and they differ from younger patients. They are a heterogeneous population that cannot be defined only by age but should rather be stratified based on their frailty. The elderly have distinctive pharmacokinetic and pharmacodynamic characteristics, are frequently polymorbid, and are therefore treated with multiple drugs. They may experience adverse reactions that are difficult to recognize, since some of them present non-specific symptoms easily mistaken for geriatric conditions. Paradoxically, the elderly are underrepresented in clinical trials, especially the frail individuals whose pharmacological response and expected treatment outcome can be different from those of non-frail patients. This means that the benefit–risk balance of drugs used in frail elderly patients is frequently unknown. We present some proposals to overcome the barriers preventing the enrollment of frail elderly patients in clinical trials, and strategies for monitoring their therapy to minimize the risk of adverse reactions. Automated alerts for drug and drug–disease interactions could help appropriate prescribing but should flag only clinically relevant interactions. Pharmaceutical forms should be designed to allow easy dose adjustment and, together with packaging and labeling, should account for the physical and cognitive limitations of frail elderly patients. Aggregate pharmacovigilance reports should summarize the safety profile in the elderly, but rather than presenting the results by age they should focus on patients’ frailty, perhaps using the number of comorbidities as a proxy when information on frailty is not available.

Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-020-00949-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:43:y:2020:i:9:d:10.1007_s40264-020-00949-w

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-020-00949-w

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().